Histogenics Corporation to Present at Upcoming Investor Conferences

Histogenics Corporation to Present at Upcoming Investor Conferences

Share this story with your network

WALTHAM, Mass., Feb. 23, 2017 (GLOBE NEWSWIRE) — Histogenics Corporation (Histogenics) (HSGX), a regenerative medicine company focused on developing and commercializing products in the musculoskeletal space, today announced that Company Management will be presenting at two upcoming healthcare investor conferences.

  • Cowen and Company 37th Annual Health Care Conference – Boston, MA (March 6-8, 2017)

    Adam Gridley, Histogenics’ CEO, will be presenting a corporate overview on Monday, March 6, 2017, at 4:00 pm EST.
  • Canaccord Genuity 2017 Musculoskeletal Conference – San Diego (March 14, 2017)

    Adam Gridley, Histogenics’ CEO, will be presenting a corporate overview on Tuesday, March 14, 2017 at 3:30 pm PST.  The conference immediately precedes the American Academy of Orthopaedic Surgeons (AAOS) Annual Meeting and explores the current state of orthopedics, biologics, imaging, robotic surgery, tissue sculpting, and regenerative tissue companies.

The live webcasts for the presentations listed above may be accessed by visiting the Investor Relations section of Histogenics’ website at www.histogenics.com.  The webcasts will be available on Histogenics’ website for approximately 45 days following the respective conferences.

About Histogenics Corporation

Histogenics is a leading regenerative medicine company developing and commercializing products in the musculoskeletal segment of the marketplace.  Histogenics’ regenerative medicine platform combines expertise in cell processing, scaffolding, tissue engineering, bioadhesives and growth factors to provide solutions to treat musculoskeletal-related conditions.  Histogenics’ first investigational product candidate, NeoCart, is currently in Phase 3 clinical development.  NeoCart is an autologous cell therapy designed to treat cartilage defects in the knee using the patient’s own cells.  Knee cartilage defects represent a significant opportunity in the United States, with an estimated 500,000 or more applicable procedures each year.  NeoCart is designed to exhibit characteristics of articular, hyaline cartilage prior to and upon implantation into the knee and therefore does not rely on the body to make new cartilage, characteristics not exhibited in other current treatment options.  For more information, please visit www.histogenics.com.

Leave a Comment

Your email address will not be published. Required fields are marked *

*